Skip to content
  1. Home/
  2. Latest news/
  3. What you need to know about Johnson & Johnson’s 2025 first-quarter earnings
Johnson & Johnson scientists in lab coats handling pipettes

What you need to know about Johnson & Johnson’s 2025 first-quarter earnings

Here’s an infographic breakdown of the company’s first-quarter earnings results, including highlights from its Innovative Medicine and MedTech businesses.

This morning, Johnson & Johnson shared its 2025 first-quarter earnings report.

Since its founding in 1886, the company has been committed to innovation—today, more than 138,000 employees across the globe work to deliver solutions for patients around the world and to help profoundly impact health for humanity.

Johnson & Johnson’s diversified business model uniquely positions us to navigate challenges while delivering on our financial commitments, advancing an innovative pipeline and creating long-term, sustainable value for shareholders,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “Our solid results and strong financial foundation enable us to invest for the future, bolster our portfolio and return capital to our shareholders, as evidenced by today’s announcement of our 63rd consecutive year of dividend increases.”

For more details about the company’s 2025 first-quarter results, and to read a message from Chairman and Chief Executive Officer Joaquin Duato, here’s an infographic highlighting key stats.

Infographic of Q1 2025 Earnings Johnson & Johnson

Johnson & Johnson’s 2025 first-quarter earnings

Read the earnings press release, which includes full financial data for the first quarter of 2025.

Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.

More from Johnson & Johnson

Johnson & Johnson named to Fortune’s 2025 America’s Most Innovative Companies list

The company’s commitment to developing solutions that tackle the world’s most pressing health challenges has helped Johnson & Johnson be recognized as the top-ranked healthcare company on the list.

Inside Johnson & Johnson’s decades-long quest to develop effective treatments for IBD

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.